Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ:AQST) refinanced its existing debt with a new $150 million five-year facility from Oaktree Capital Management. The deal funds repayment of a $45 million loan and offers interest-only payments with principal due at maturity.
The facility includes an initial $55 million funded at closing, $20 million upon FDA approval of Anaphylm and other conditions, a $25 million sales milestone tranche, and up to $50 million subject to mutual consent, enhancing flexibility for a potential Anaphylm launch and meeting conditions under a strategic funding agreement with RTW Investments.
AI-generated analysis. Not financial advice.
Positive
- New Oaktree facility totals $150 million across four tranches
- Initial $55 million used to repay prior $45 million loan and fees
- Principal debt repayments over next three years cut from $45 million to zero
- Interest rate reduced versus previous debt agreement, according to Aquestive
- Five-year term with interest-only payments and principal due at maturity
- Pre-approval requirements met under RTW strategic funding agreement, unlocking additional capital
Negative
- All principal on the new facility becomes due as a single maturity payment
- Access to an additional $20 million depends on FDA approval of Anaphylm and other conditions
- Further $25 million tranche contingent on specified sales milestones being achieved
- Final tranche of up to $50 million requires mutual consent of lenders and company
News Market Reaction – AQST
On the day this news was published, AQST declined 4.15%, reflecting a moderate negative market reaction. Argus tracked a peak move of +13.3% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $517.02M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AQST showed a modest 0.46% gain while key peers were mixed; AKBA appeared in momentum scans up 2.17%, but no broad, same-direction move across sector peers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings timing update | Neutral | +1.2% | Announcement of Q1 2026 results timing and related conference call. |
| Mar 30 | Regulatory update | Positive | +0.5% | Completion of Type A FDA meeting and clarity on Anaphylm NDA path. |
| Mar 20 | Management change | Neutral | -2.0% | Appointment of new Chief Legal and Compliance Officer with equity awards. |
| Mar 09 | Inducement awards | Neutral | -2.1% | Equity inducement grants to new Chief Medical Officer under plan. |
| Mar 04 | Earnings and CRL | Negative | -2.5% | Q4 growth offset by FDA Complete Response Letter for Anaphylm. |
Recent AQST news has often seen modest price moves, with some negative reactions around financial and governance updates.
Over the last six months, Aquestive has mixed operational and regulatory milestones. On Mar 4, 2026, Q4 2025 results showed $13.0M revenue, a 10% rise, but the stock fell 2.52% after a Complete Response Letter for Anaphylm. Subsequent governance and inducement-award announcements in March saw small negative reactions. Regulatory progress for Anaphylm and an upcoming Q1 2026 report, announced on Mar 30 and May 6, drew mild positive moves. Today’s refinancing strengthens liquidity ahead of potential Anaphylm commercialization.
Market Pulse Summary
This announcement details a refinancing into a $150.0M Oaktree facility, with $55.0M funded at close and additional tranches of $20.0M, $25.0M, and up to $50.0M tied to FDA approval, sales milestones, and mutual consent. The five-year, interest-only structure reduces near-term principal payments versus the prior $45.0M loan. Investors may track execution on Anaphylm’s regulatory path, use of proceeds, and future debt-service capacity as key markers following this transaction.
Key Terms
principal amount financial
tranche financial
royalty financing financial
AI-generated analysis. Not financial advice.
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new
This transaction provides additional flexibility to fund the launch of Anaphylm™, if approved by the FDA. At closing, Oaktree provided
“We are excited to begin our relationship with Oaktree, a well-established leader within life sciences debt financing,” said Daniel Barber, CEO of Aquestive Therapeutics. “The new
"We are delighted to be partnering with Aquestive at this exciting stage in the company's development and believe that Anaphylm has the potential to be a truly transformative rescue treatment for patients suffering from severe allergic reactions, including anaphylaxis,” said Rahul Anand, Managing Director, Life Sciences Lending at Oaktree. “This transaction underscores Oaktree’s commitment to provide scalable capital solutions to companies developing novel medicines. We look forward to supporting the Aquestive management team as they work on bringing this important therapy to patients and healthcare providers globally.”
Oaktree is a leading provider of debt and royalty financing for the global life sciences industry. Since 2020, funds managed by Oaktree have committed more than
Cantor Fitzgerald acted as the sole placement agent to Aquestive. Dechert LLP acted as counsel to Aquestive and Morgan, Lewis & Bockius LLP served as counsel to Oaktree.
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for various potential dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
About Anaphylm™ (dibutepinephrine) Sublingual Film
Anaphylm™ (dibutepinephrine) sublingual film is a polymer matrix-based epinephrine prodrug investigational drug product. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The primary packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.
About Oaktree
Oaktree is a leader among global investment managers specializing in alternative investments, with
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidates, including Anaphylm™ (dibutepinephrine) sublingual film and AQST-108 (epinephrine prodrug) topical gel, through clinical development and approval by the U.S. Food and Drug Administration (FDA) for the respective targeted indications; the advancement and related timing of potential international regulatory filings and marketing authorization of Anaphylm outside of the U.S.; and that Anaphylm will be the first and only oral administration of epinephrine, if Anaphylm is approved by the FDA. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm and AQST-108, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries
Astr Partners
Brian Korb
Brian.korb@astrpartners.com
